Long-term Safety of Minimally Invasive Left Ventricular Assist Device Discontinuation for Myocardial Recovery.

Autor:	Kapoor K; Department of Internal Medicine, Jackson Memorial Hospital/University of Miami, Miami, Florida. Electronic address: kunal.kapoor@jhsmiami.org., Shah P; Department of Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, Virginia., Bogar LJ; Department of Cardiac Surgery, Inova Heart and Vascular Institute, Falls Church, Virginia., Edwards LG; Department of Heart Failure and Transplantation, Inova Heart and Vascular Institute, Falls Church, Virginia., Panjrath GS; Department of Heart Failure, George Washington University, Washington, DC., Singh R; Department of Cardiac Surgery, Inova Heart and Vascular Institute, Falls Church, Virginia.
Jazyk:	angličtina
Zdroj:	The Annals of thoracic surgery [Ann Thorac Surg] 2019 Nov; Vol. 108 (5), pp. 1398-1403. Date of Electronic Publication: 2019 Jun 04.
DOI:	10.1016/j.athoracsur.2019.04.042
Abstrakt:	Background: Left ventricular assist devices (LVADs) play important roles in advanced heart failure (HF) management. In patients who experience myocardial recovery, the LVAD is often explanted via a resternotomy, which may negatively impact the newly recovered heart. We describe a case-series of LVAD discontinuation using a minimally invasive approach, focusing on thromboembolic phenomenon and infection rates in long-term follow-up. Methods: Our study is a single-center, retrospective case series of patients with myocardial recovery after mechanical unloading with an LVAD. Patients underwent outflow graft ligation through a minimally invasive approach with driveline excision. Postdiscontinuation, patients obtained serial transthoracic echocardiograms for a minimum of 6 months and followed with our heart failure specialist. Results: All 7 recovery patients had nonischemic cardiomyopathy and included 4 women (57%). Mean age was 44.3 ± 15.6 years. Median LVAD support duration was 454 (interquartile range, 326 to 1096) days. Intensive care unit length of stay and total length of stay were 3.4 ± 1.9 days and 6.3 ± 2.3 days, respectively. Blood transfusion rate was 0.86 ± 1.1 units. At a median follow-up of 874 (interquartile range, 864 to 1007) days, no patients developed thromboembolic phenomena despite use of aspirin only for prophylaxis. One patient experienced driveline infection, who had persistent driveline infection before procedure. Conclusions: This minimally invasive approach for LVAD discontinuation through outflow graft ligation, driveline removal, and LVAD stoppage in setting of myocardial recovery avoids resternotomy risks. Despite leaving the LVAD in situ, there was no risk of thromboembolism or infection associated with residual hardware. (Copyright © 2019 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu